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Abstract
Background: Anti tumor necrosis factor agents are a valuable addition to the armamentarium
against rheumatoid arthritis but have some serious side effects which clinicians should be aware
about.
Case presentation: We present a case of a 54 year old Caucasian male with refractory
rheumatoid arthritis who developed mononeuritis multiplex four weeks after starting adalimumab
therapy.
Conclusion: Complete resolution of neurological and electromyography findings was seen upon
stopping therapy. These agents can be a double-edged sword in the management of
rheumatological illnesses. Though they help treat refractory disease, their potential side effects can
include mononeuritis multiplex which can be recognized by means of clinical features,
electromyography and nerve biopsy as depicted in our case.
Background
Anti tumor necrosis factor (TNF) agents are emerging in
the frontline management of rheumatoid arthritis (RA) in
the current era of biologicals. They have considerable side
effects including infections, malignancies, and hypersen-
sitivity reactions. Vasculitis leading to mononeuritis mul-
tiplex (MM) is a rare but potentially serious complication
of RA and has been previously reported after infliximab
therapy [1]. We present a patient with RA who developed
MM on adalimumab therapy.
Case presentation
A 54 year old Caucasian male with a history of RA for last
25 years refractory to multiple medications including
gold, methotrexate, cyclosporine and leflunomide was
started on adalimumab 4 weeks prior to presentation. He
presented with progressively increasing pain, parasthesias
and numbness of bilateral upper and lower extremities of
2 weeks duration followed by a right wrist and left foot
drop. He lost 25 lbs weight during this period. He denied
any history of smoking or alcohol intake. He was on per-
manent disability secondary to severe destructive joint
disease with his RA. He did not have any prior neurologi-
cal problems. Other medical problems included hyper-
tension and gastroesophageal reflux disease for which he
was on lisinopril and famotidine respectively. He had ton-
sillectomy and adenoidectomy as a child. There was no
significant family history. He weighed 100 lbs and was 5
foot 7 inch tall. Physical examination revealed ulnar devi-
ation with swan neck and boutonniere deformities of the
fingers bilaterally. Paresis of dorsiflexion and eversion of
the right foot and dorsiflexion of the left wrist were also
present. Rheumatoid factor titer was high at 337 IU/ml,
ESR and CRP elevated at 84 mm/h and 5.9 mg/dl respec-
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tively and C4 level was low at 12 indicating high disease
activity. A work up for peripheral neuropathy revealed
normal TSH, Vitamin B, CPK and Acetyl-L-carnitine levels.
Monospot test, VDRL, HIV antibody, P- and C-ANCA,
ANA, anti double-stranded DNA, heavy metal screen and
a paraneoplastic panel were all negative. Serologies for
hepatitis and borrelia were negative. MRI of the spine
ruled out cord lesion. Electromyography (EMG) of the left
upper extremity and right lower extremity showed axonal
neuropathy with spontaneous activity and sharp wave
fibrillation potentials. Sural nerve biopsy revealed focal
segmental necrotizing arteritis with fibrinoid necrosis,
loss of thick fibres and axonal degeneration consistent
with MM. Adalimumab was stopped and high dose meth-
ylprednisolone (40 mg q12h) and cyclosporine (25 mg
q12h) were started which led to resolution of symptoms.
He was discharged on oral prednisone and cyclophospha-
mide. Resolution of neurological symptoms and EMG
abnormalities were noted at three months follow up. He
regained 18 lbs of his lost weight during these 3 months.
Discussion
MM is a painful, asymmetric, asynchronous sensory and
motor peripheral neuropathy involving at least 2 separate
nerves and often associated with constitutional features
including fatigue and significant weight loss. It is a rare
but known complication of long-standing RA secondary
to vasculitic neuropathy. Anti TNF agents have been
reported in successful treatment of neuropathy in RA.
However, flare up of neuropathy has also been reported
with these agents[2,3]. In particular, infliximab therapy
has been associated with multifocal motor neuropathy
with conduction block as well as axonal sensory polyneu-
ropathy which reversed upon discontinuation of inflixi-
mab and intravenous gammaglobulin treatment [2].
Mechanisms proposed include induction of auto-anti-
bodies and T cell mediated cytokines. MS patients treated
with these agents showed an increase in gadolinium-
enhancing lesions on MRI[4] and the number of flares[5]
indicating that TNF-α might have a protective role against
inflammation and demyelination. Though a progression
of RA or a de novo onset of vasculitis cannot be excluded,
the temporal association of symptoms on starting adali-
mumab and their subsequent disappearance on stopping,
and a negative work up for other possible causes of MM,
is indicative of a drug induced phenomenon.
Conclusion
TNF antagonists represent a major breakthrough in the
treatment of rheumatologic diseases but are not without
potentially serious adverse effects. To our knowledge this
is the first report of association of MM with adalimumab.
Future studies are needed to assess the possible associa-
tion of anti-TNF-agents with MM in order to assist clini-
cians with appropriate clinical decision-making.
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